Clinical Trial Update: Reducing Breathlessness With Dronabinol in COPD Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update indicates dronabinol is being studied to reduce breathlessness in COPD patients and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Dronabinol (dronabinol)

Snippet

Sponsor: Vejle Hospital | Conditions: COPD, Breathlessness | Phase 3 | Status: RECRUITING